Intended for healthcare professionals

Clinical Review State of the Art Review

Covid-19 vaccination in pregnancy

BMJ 2022; 378 doi: https://doi.org/10.1136/bmj-2021-069741 (Published 10 August 2022) Cite this as: BMJ 2022;378:e069741
  1. Martina L Badell, associate professor1,
  2. Carolynn M Dude, assistant professor1,
  3. Sonja A Rasmussen, professor2 ,
  4. Denise J Jamieson, professor and chair1
  1. 1Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA. USA
  2. 2Departments of Pediatrics and Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, FL, USA
  1. Correspondence to: Denise J Jamieson djamieson{at}emory.edu

ABSTRACT

Pregnancy is an independent risk factor for severe covid-19. Vaccination is the best way to reduce the risk for SARS-CoV-2 infection and limit its morbidity and mortality. The current recommendations from the World Health Organization, Centers for Disease Control and Prevention, and professional organizations are for pregnant, postpartum, and lactating women to receive covid-19 vaccination. Pregnancy specific considerations involve potential effects of vaccination on fetal development, placental transfer of antibodies, and safety of maternal vaccination. Although pregnancy was an exclusion criterion in initial clinical trials of covid-19 vaccines, observational data have been rapidly accumulating and thus far confirm that the benefits of vaccination outweigh the potential risks. This review examines the evidence supporting the effectiveness, immunogenicity, placental transfer, side effects, and perinatal outcomes of maternal covid-19 vaccination. Additionally, it describes factors associated with vaccine hesitancy in pregnancy. Overall, studies monitoring people who have received covid-19 vaccines during pregnancy have not identified any pregnancy specific safety concerns. Additional information on non-mRNA vaccines, vaccination early in pregnancy, and longer term outcomes in infants are needed. To collect this information, vaccination during pregnancy must be prioritized in vaccine research.

Footnotes

  • Series explanation: State of the Art Reviews are commissioned on the basis of their relevance to academics and specialists in the US and internationally. For this reason they are written predominantly by US authors

  • Contributors: All authors defined the intellectual content, conducted the literature research, acquired data, and participated in preparing, editing, and critically reviewing the manuscript. DJJ is the guarantor.

  • Competing interests: We have read and understood the BMJ policy on declaration of interests and declare: MLB and CMD receive NIH grant funding for DMID 21-0004, an observational, prospective cohort study of the immunogenicity and safety of SARS-CoV-2 vaccines administered during pregnancy or post partum and evaluation of antibody transfer and durability in infants.

  • Provenance and peer review: Commissioned; externally peer reviewed.

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription